Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients?

Over the last decade, increasing numbers of oesophageal cancer patients have been treated with radiotherapy, either in the neo-adjuvant setting followed by surgery or as definitive treatment. Due to neo-adjuvant CRT, cure rates have improved [1,2]. As a consequence, the number of oesophageal cancer survivors at risk of developing late toxicity is has risen correspondingly.

Source: Radiotherapy and Oncology - May 19, 2020 Category: Radiology Authors: Jannet C. Beukema, Yoshifumi Kawaguchi, Nanna M. Sijtsema, Tian-Tian Zhai, Johannes A. Langendijk, Lisanne V. van Dijk, Peter van Luijk, Teruki Teshima, Christina T. Muijs Tags: Original Article Source Type: research